Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.49 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.49 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.49 |
| ▸ | PRKCA | P17252 | 1/20 | 0.49 |
| ▸ | NAAA | Q02083 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL483499 | 1.00 | DGKA (0.55) | DGKAFAAHALDH1A1CNR1CNR2 | |
| SCHEMBL5482407 | 1.00 | DGKA (0.55) | DGKAFAAHALDH1A1CNR1CNR2 | |
| SCHEMBL407730 | 1.00 | DGKA (0.55) | DGKAFAAHALDH1A1CNR1CNR2 | |
| SCHEMBL18662301 | 0.95 | ALDH1A1 (0.57) | DGKAFAAHALDH1A1CNR1CNR2 | |
| Phosphoric Acid SCHEMBL4261864 | 0.94 | LPAR1 (0.51) | DGKAFAAH | |
| SCHEMBL23121501 | 0.90 | NAAA (0.59) | NAAA | |
| SCHEMBL118318 | 0.90 | NAAA (0.59) | NAAA | |
| SCHEMBL114472 | 0.90 | NAAA (0.59) | NAAA | |
| SCHEMBL117824 | 0.90 | NAAA (0.59) | NAAA | |
| SCHEMBL23467113 | 0.90 | NAAA (0.59) | NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140044786-A1 | ONCE-WEEKLY ORAL ADMINISTRATION OF ARIPIPRAZOLE | ZYSIS LIMITED (GB) | 2014-02-13 | — | — | US | claimed |
| US-8242165-B2 | Mucoadhesive nanoparticles for cancer treatment | CREIGHTON UNIVERSITY (US) | 2012-08-14 | — | — | US | claimed |
| WO-2011050388-A1 | LIQUID CRYSTAL COMPOSITION AND METHOD OF USE | MONASH UNIVERSITY (AU) | 2011-05-05 | — | — | WO | claimed |
| US-20100323977-A9 | Mucoadhesive nanoparticles for cancer treatment | US ARMY, SECRETARY OF THE ARMY | 2010-12-23 | — | — | US | claimed |
| US-20090275526-A1 | Mucoadhesive nanoparticles for cancer treatment | DASH ALEKHA K | 2009-11-05 | — | — | US | claimed |
| US-12605333-B2 | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release | TRIS PHARMA, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260096986-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A FLOATING INTERPENETRATING POLYMER NETWORK FORMING SYSTEM | TRIS PHARMA INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-12569508-B2 | Antimicrobial compositions and methods of use | UNIV SOUTH AUSTRALIA (AU) | 2026-03-10 | — | — | US | disclosed |
| US-12521342-B2 | Fast disintegrating tablet | CUBOPHARM PTY LTD (AU) | 2026-01-13 | — | — | US | disclosed |
| US-12521350-B2 | Liquid crystalline dosage form for administering a statin | CUBOPHARM PTY LTD (AU) | 2026-01-13 | — | — | US | disclosed |
| US-12514818-B2 | Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system | TRIS PHARMA, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250339517-A1 | LIPID NANOCARRIER VACCINE | MELBOURNE INST TECH (AU) | 2025-11-06 | — | — | US | disclosed |
| US-20100323977-A9 | Mucoadhesive nanoparticles for cancer treatment | US ARMY, SECRETARY OF THE ARMY | 2010-12-23 | — | — | US | disclosed |
| US-20070108405-A1 | Compositions and methods for delivery of biologically active agents | FH FAULDING & CO., LTD. (AU) | 2007-05-17 | — | — | US | disclosed |
| EP-1534669-A4 | UREA-, GLYCERATE- AND, HYDROXYAMIDE-HEADED HYDROCARBON CHAIN LYOTROPIC PHASES FORMING SURFACTANTS | MAYNE PHARMA INT PTY LTD (AU) | 2007-03-14 | — | — | EP | disclosed |
| EP-1667656-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | FH Faulding & Co. Limited (AU) | 2006-06-14 | — | — | EP | disclosed |
| US-20050249665-A1 | Urea-, glycerate- and, hydroxyamide-headed hydrocarbon chain lyotropic phases forming surfactants | DBL AUSTRALIA PTY LTD. (AU) | 2005-11-10 | — | — | US | disclosed |
| EP-1534669-A1 | UREA-, GLYCERATE- AND, HYDROXYAMIDE-HEADED HYDROCARBON CHAIN LYOTROPIC PHASES FORMING SURFACTANTS | DBL Australia PTY. LTD. (AU) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005021046-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | FH FAULDING & CO LTD (AU) | 2005-03-10 | — | — | WO | disclosed |
| WO-2004022530-A1 | UREA-, GLYCERATE- AND, HYDROXYAMIDE-HEADED HYDROCARBON CHAIN LYOTROPIC PHASES FORMING SURFACTANTS | DBL AUSTRALIA PTY LTD (AU) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275526-A1 | Mucoadhesive nanoparticles for cancer treatment | PNLIP, MUC1, LIPA | DGKA 146/4885FAAH 390/4885ALDH1A1 1964/4885 |
| US-12569508-B2 | Antimicrobial compositions and methods of use | PCTP, PYCARD, PLIN3 | DGKA 1890/4885FAAH 1561/4885ALDH1A1 4554/4885 |
| US-20140044786-A1 | ONCE-WEEKLY ORAL ADMINISTRATION OF ARIPIPRAZOLE | CYP2A6, CYP2C19, CYP2D6 | DGKA 3386/4885FAAH 126/4885ALDH1A1 759/4885 |
| US-20260096986-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A FLOATING INTERPENETRATING POLYMER NETWORK FORMING SYSTEM | SI, FABP2, FABP6 | DGKA 1362/4885FAAH 330/4885ALDH1A1 684/4885 |
| US-12605333-B2 | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release | SI, GRPR, FABP2 | DGKA 1543/4885FAAH 252/4885ALDH1A1 3208/4885 |
| US-20050249665-A1 | Urea-, glycerate- and, hydroxyamide-headed hydrocarbon chain lyotropic phases forming surfactants | LIPA, HDHD5, UGCG | DGKA 475/4885FAAH 41/4885ALDH1A1 4133/4885 |
| US-20100323977-A9 | Mucoadhesive nanoparticles for cancer treatment | PNLIP, MUC1, LIPA | DGKA 146/4885FAAH 390/4885ALDH1A1 1964/4885 |
| US-20250339517-A1 | LIPID NANOCARRIER VACCINE | CD47, LY96, TSG101 | DGKA 826/4885FAAH 1756/4885ALDH1A1 4427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.